In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price target of $28.00. The company’s shares closed today at $9.58.
According to TipRanks, Syed is an analyst with an average return of -14.5% and a 37.50% success rate. Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Coherus Biosciences, and Atara Biotherapeutics.
Coherus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $22.75.
See today’s best-performing stocks on TipRanks >>
Based on Coherus Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $60.15 million and a GAAP net loss of $50.15 million. In comparison, last year the company earned a revenue of $87.64 million and had a GAAP net loss of $29.9 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Read More on CHRS:
- Coherus Biosciences to launch CIMERLI in the U.S. on October 3
- Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
- Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
- Coherus BioSciences Announces New Employment Inducement Grants
- Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update